IRIS
CICONE, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.757
AS - Asia 1.583
EU - Europa 542
SA - Sud America 539
AF - Africa 37
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 4.469
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.693
SG - Singapore 735
BR - Brasile 416
CN - Cina 288
VN - Vietnam 234
IT - Italia 198
IN - India 120
GB - Regno Unito 66
AR - Argentina 53
HK - Hong Kong 52
SE - Svezia 48
ID - Indonesia 43
NL - Olanda 37
CA - Canada 36
FR - Francia 32
DE - Germania 28
EC - Ecuador 25
BD - Bangladesh 24
MX - Messico 22
EE - Estonia 21
RO - Romania 20
ZA - Sudafrica 18
CO - Colombia 16
CZ - Repubblica Ceca 14
GR - Grecia 13
RU - Federazione Russa 12
FI - Finlandia 11
PY - Paraguay 11
JP - Giappone 9
CL - Cile 8
IR - Iran 8
PH - Filippine 7
UZ - Uzbekistan 7
AU - Australia 6
CH - Svizzera 6
IQ - Iraq 6
LV - Lettonia 6
MY - Malesia 6
TR - Turchia 6
PE - Perù 5
UA - Ucraina 5
KE - Kenya 4
KR - Corea 4
PT - Portogallo 4
TN - Tunisia 4
TW - Taiwan 4
UY - Uruguay 4
AT - Austria 3
ES - Italia 3
EU - Europa 3
IE - Irlanda 3
IL - Israele 3
JO - Giordania 3
KZ - Kazakistan 3
PK - Pakistan 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BE - Belgio 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EG - Egitto 2
GH - Ghana 2
JM - Giamaica 2
MA - Marocco 2
NP - Nepal 2
PL - Polonia 2
SA - Arabia Saudita 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
DK - Danimarca 1
ET - Etiopia 1
FJ - Figi 1
GW - Guinea-Bissau 1
HN - Honduras 1
HR - Croazia 1
LB - Libano 1
LT - Lituania 1
LY - Libia 1
MM - Myanmar 1
MN - Mongolia 1
NO - Norvegia 1
OM - Oman 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.469
Salva come PNG Salva come JPEG
Città #
San Jose 324
Singapore 278
Chandler 181
Ashburn 168
Dallas 126
Santa Clara 105
Bengaluru 99
Hefei 99
Ho Chi Minh City 94
Princeton 70
Lawrence 69
Milan 63
Hong Kong 52
Wilmington 46
Beijing 43
Hanoi 40
London 40
Chicago 35
São Paulo 31
Los Angeles 26
Ottawa 24
Jakarta 19
Boardman 17
Des Moines 17
Rome 15
Haiphong 13
The Dalles 12
Belo Horizonte 11
Guayaquil 11
Timisoara 11
Nijmegen 10
Rio de Janeiro 10
West Jordan 10
Columbus 9
Da Nang 9
Johannesburg 9
Munich 9
Norwalk 9
Bayonne 8
Chennai 8
Council Bluffs 8
Naples 8
New York 8
Redmond 8
Campinas 7
Charlotte 7
Guarulhos 7
Horia 7
Mexico City 7
San Francisco 7
Shanghai 7
Stockholm 7
Boston 6
Brasília 6
Dhaka 6
Hanover 6
Helsinki 6
Lanskroun 6
Manchester 6
Ninh Bình 6
Olomouc 6
Redwood City 6
Riga 6
Santo André 6
Tashkent 6
Toronto 6
Amsterdam 5
Asunción 5
Atlanta 5
Biên Hòa 5
Buenos Aires 5
Guangzhou 5
Kuala Selangor 5
Massy 5
Poplar 5
Porto Alegre 5
Quito 5
Recife 5
Tokyo 5
Turku 5
Ankara 4
Ann Arbor 4
Assago 4
Bogotá 4
Brooklyn 4
Bắc Giang 4
Can Tho 4
Caxias do Sul 4
Fortaleza 4
Isfahan 4
L'aquila 4
Manila 4
Nairobi 4
New Delhi 4
Oosterbeek 4
Paola 4
Pereira 4
San Diego 4
São Gonçalo 4
Wuxi 4
Totale 2.552
Salva come PNG Salva come JPEG
Nome #
Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors 104
Volumetric assessment of gliomas: Comparison between F-18-FET and Ga-68-NODAGA-RGDyK 89
A Monte Carlo model for the internal dosimetry of choroid plexuses in nuclear medicine procedures 84
Correction to: Preclinical Evaluation and Dosimetry of [111In] CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1) (Molecular Imaging and Biology, (2020), 22, 4, (979-991), 10.1007/s11307-020-01479-8) 82
F-DOPA PET identifies high tumor grade and anaplastic transformation in non-enhancing gliomas 82
Anatomical substrates of cognitive and clinical dimensions in first episode schizophrenia 81
In-111-PCTA-VRC07 a Radiolabeled Broadly Neutralizing Antibody For HIV Imaging in Mice 79
A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin) 78
Impact of chemotherapy with Temozolomide on physiological brain 18F-DOPA uptake in patients with glioma 77
Preclinical evaluation of a single-chain variable anti TEM-1 fragment labeled with In-111 and Tb-152 77
Amino acid PET and MR perfusion imaging in brain tumours 77
"Boom-Boom" radioimmunotherapy of lymphomas: Are two magic bullets better than one? 75
18 F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma 68
Cardiac radionuclide imaging in rodents: A review of methods, results, and factors at play 68
Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery 65
Value of F-DOPA PET in the long term follow up of radionecrotic brain metastases after radiosurgery: comparison with MRI 64
Advanced imaging techniques for radiotherapy planning of gliomas 63
Do we need dosimetry for the optimization of theranostics in CNS tumors? 62
Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0 59
18F-DOPA Positron Emission Tomography in Medulloblastoma: 2 Case Reports 59
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting 58
18F-PSMA-1007 salivary gland dosimetry: comparison between different methods for dose calculation and assessment of inter- and intra-patient variability 55
First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68 Ga-NODAGA-MJ9 54
Central nervous system- Primary and secondary Tumours: Radiolabelled Amino Acids 54
18F-DOpA uptake parameters in glioma: Effects of patients’ characteristics and prior treatment history 54
Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET 54
Cross-sectional evaluation of FGD-avid polyostotic fibrous dysplasia: MRI, CT and PET/MRI findings 54
Central nervous system - Primary tumours 53
Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial 52
Thyro-entero-gastric autoimmunity: Pathophysiology and implications for patient management 52
Editorial: Perspectives in Small Animal Radionuclide Imaging 52
Repeated stereotactic radiosurgery for patients with progressive brain metastases 52
Comparison of absorbed dose extrapolation methods for mouse-to-human translation of radiolabelled macromolecules 52
The contest between internal and external-beam dosimetry: The Zeno's paradox of Achilles and the tortoise 52
Impaired insulin-stimulated myocardial glucose metabolic rate is associated with reduced estimated myocardial energetic efficiency in subjects with different degrees of glucose tolerance 51
EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials 51
Editorial: Nuclear Medicine in the Context of Personalized Medicine 51
Quantification of dose nonuniformities by voxel-based dosimetry in patients receiving 90Y-ibritumomab-tiuxetan 50
Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan 50
ROLE OF 18F-DOPA PET/CT IN NON-ENHANCING GLIOMAS 50
Single-fraction versus multifraction (3 × 9 gy) stereotactic radiosurgery for large (>2 cm) brain metastases: A comparative analysis of local control and risk of radiation-induced brain necrosis 50
Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1) 49
Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI 49
In Reply to the Letter to the Editor Regarding “18F-DOPA PET in Medulloblastoma: Two Case Reports” 49
Reply to: "assessment of imaging biomarkers in the follow-up of brain metastases after SRS" 49
Elevated whole blood viscosity is associated with an impaired insulin-stimulated myocardial glucose metabolism 49
Erratum to: Amino acid PET and MR perfusion imaging in brain tumours (Clinical and Translational Imaging, (2017), 5, 3, (209-223), 10.1007/s40336-017-0225-z) 48
Hyperhomocysteinemia in acute iatrogenic hypothyroidism: the relevance of thyroid autoimmunity 48
Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice 48
LONG TERM FOLLOW UP OF RADIONECROTIC BRAIN METASTASES ASSESSED BY SERIAL F-DOPA PET/CT SCANS 47
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands 47
Not all that glitters is COVID! Differential diagnosis of FDG-avid interstitial lung disease in low-prevalence regions 46
Multiparametric evaluation of low grade gliomas at followup: Comparison between diffusion and perfusion MR with 18F-FDOPA PET 46
Tc-99m DTPA cisternography shows disappearance of cerebrospinal fluid leakage after standing a short time 45
Comment on hatzoglou et al: Dynamic contrastenhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury 44
The importance of standardizing acquisition settings and interpretation criteria of radionuclide cisternography 44
Follicular lymphoma at relapse after rituximab containing regimens: Comparison of time to event intervals prior to and after 90Y-ibritumomab-tiuxetan 44
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group 43
Repeated amino acid PET imaging for longitudinal monitoring of brain tumors 42
Erratum: Tc-99m DTPA cisternography shows disappearance of cerebrospinal fluid leakage after standing a short time (Clinical Nuclear Medicine (2009)(29-30)) 42
Fatal pulmonary tumour thrombotic microangiopathy: do typical FDG-PET findings exist? 42
Monte Carlo 90Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation 42
Dosimetry-based treatment planning for molecular radiotherapy: A summary of the 2017 report from the Internal Dosimetry Task Force 42
Why not consider PET/CT in the workup of pulmonary tumour thrombotic microangiopathy? 42
Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimization 42
Unespected dectection of unruptured brain arteriovenous malformation with 18F-DOPA PET/MR 41
Radioimmunotherapy of heavily pre-treated, non-Hodgkin's lymphoma patients: efficacy and safety in a routine setting 41
Immune-related [18F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications 40
Metabolic Evolution of Brain Metastasis after Stereotactic Radiosurgery: Mismatch between F-DOPA and FDG PET 40
Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases 40
Functional connectivity of the cortico-subcortical sensorimotor loop is modulated by the severity of nigrostriatal dopaminergic denervation in Parkinson's Disease 39
Fundamentals of internal radiation dosimetry 38
Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study 38
LONGITUDINAL HYBRID PET/MRI IN JUVENILE-ONSET HUNTINGTON DISEASE (JOHD) 38
THE RELATIONSHIP BETWEEN BRAIN STRUCTURE AND GLUCOSE METABOLISM VARIES OVER TIME IN JUVENILE-ONSET HUNTINGTON DISEASE 37
Translating the theranostic concept to neuro-oncology: disrupting barriers 37
First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK 36
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update 35
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey 35
Studying the metabolic activity of red bone marrow by means of FDG-PET: The need for a standardization 35
Metabolic Syndrome Is Associated With Impaired Insulin-Stimulated Myocardial Glucose Metabolic Rate in Individuals With Type 2 Diabetes: A Cardiac Dynamic 18F-FDG-PET Study 34
Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases 34
Rituximab-like radiolabelled antibodies for the treatment of non-hodgkin's lymphomas 33
Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry 32
Malignant Lymphoma in Children 32
EANM enabling guide: how to improve the accessibility of clinical dosimetry 31
LONGITUDINAL BRAIN VOLUME AND GLUCOSE METABOLISM CHANGES IN PATIENTS WITH JUVENILE-ONSET HUNTINGTON DISEASE 31
Sex-specific differences in myocardial glucose metabolic rate in non-diabetic, pre-diabetic and type 2 diabetic subjects 30
Imaging the future: A report from the Young Daily EANM Forum 2013 30
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer? 28
Reply to Zaragori et al.: “Is IDH mutation status associated with 18F-FDopa PET uptake” 28
Expression of large neutral amino acid transporters LAT1 and LAT2 in medulloblastoma 28
Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck 27
FET and FDOPA PET Imaging in Glioma 26
The mean striatal 18 F-DOPA uptake is not a reliable cut-off threshold for biological tumour volume definition of glioma 26
Pediatric Huntington Disease Brains Have Distinct Morphologic and Metabolic Traits: the RAREST‐JHD Study 25
Functional connectivity of the cortico-subcortical sensorimotor loop is modulated by the severity of nigrostriatal dopaminergic denervation in Parkinson’s Disease 24
Visual and quantitative approach to bone marrow foci of increased glucose uptake on PET/CT in a case of aplastic anaemia 24
Editorial: "Nuclear medicine in cancer diagnosis" 22
Totale 4.798
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.012
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.012
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202115 0 0 0 0 0 0 0 0 0 10 1 4
2021/2022378 13 2 7 161 20 2 6 52 21 49 22 23
2022/2023523 152 44 7 46 50 32 10 35 65 33 35 14
2023/2024322 58 27 25 25 17 54 12 21 11 29 31 12
2024/2025898 125 15 18 27 81 122 29 30 140 47 108 156
2025/20262.478 103 300 364 631 261 70 213 163 280 93 0 0
Totale 4.798